Ecallantide

Plasma Kallikrein Inhibitor — BLOOD AND BLOOD FORMING ORGANS

Key facts

Ecallantide is a drug in the Plasma Kallikrein Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2009. Its mechanism of action is classified as Kallikrein Inhibitors. DrugCentral lists 1 molecular target, including KLKB1. Recorded indications include Hereditary angioneurotic edema.

• Drug class: Plasma Kallikrein Inhibitor.
• Mechanism of action: Kallikrein Inhibitors.
• Molecular targets: KLKB1 (1 listed in DrugCentral).
• Indications: Hereditary angioneurotic edema.
• ATC code: B06AC03 (Drugs used in hereditary angioedema).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Hereditary angioneurotic edema

Mechanism & targets

• Mechanism of action (MoA): Kallikrein Inhibitors
• Established pharmacologic class: Plasma Kallikrein Inhibitor

Molecular targets (1)

Target	Gene	Action	Activity
Plasma kallikrein	KLKB1	inhibitor	Ki 10.60

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2009-11-27	FDA	—	DYAX CORP.

ATC classification

ATC code	Therapeutic hierarchy
B06AC03	BLOOD AND BLOOD FORMING ORGANS › OTHER HEMATOLOGICAL AGENTS › OTHER HEMATOLOGICAL AGENTS › Drugs used in hereditary angioedema

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Hereditary angioedema	629.6
Anaphylactic reaction	88.2
Inappropriate schedule of product administration	74.8
Pharyngeal oedema	56.6
Off label use	49.1
Pharyngeal swelling	42.9
Laryngeal oedema	42.3
Therapeutic response decreased	35.7

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: —
• InChIKey: —
• PubChem CID: 44152182

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ecallantide used for?

DrugCentral lists the following indications for Ecallantide: Hereditary angioneurotic edema.

How does Ecallantide work?

Ecallantide is classified as Kallikrein Inhibitors; its molecular targets in DrugCentral include KLKB1 (inhibitor).

When was Ecallantide first approved?

Ecallantide was first approved by the FDA in 2009.

What drug class does Ecallantide belong to?

Ecallantide is in the Plasma Kallikrein Inhibitor class.

Sources

• DrugCentral drug card 4846 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201837 — compound record and bioactivity
• PubChem CID 44152182 — chemical identifiers
• DrugBank DB05311 — drug record
• FDA UNII 5Q6TZN2HNM — substance identity
• DailyMed: FDA labels for Ecallantide — current prescribing information (label search)
• UniProt P03952 (KLKB1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.